CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $239.55M, lower than 95% of all stocks globally
- PositionReturn on equity is -676.7%, lower than 95% of its Biotechnology peers (median -21.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
239.55MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.39xvs all stocks
52-Week Change
38.78%vs all stocks
Market Capitalization
239.55MUSDvs all stocks (USD)
Enterprise Value
276.31MUSDvs all stocks (USD)
Forward P/E
-23.18xvs Biotechnology peers
Price to Book (MRQ)
52.95xvs Biotechnology peers
Enterprise to EBITDA
-12.33xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-211.27%vs Biotechnology peers
Return on Equity (TTM)
-676.66%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-22.40MUSDvs all stocks (USD)
Net Income (TTM)
-22.27MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-19.45MUSDvs all stocks (USD)
Pre-tax Income
-19.36MUSDFY2025 · Dec 31, 2025Net Income
-19.36MUSDFY2025 · Dec 31, 2025EBIT
-19.45MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-19.45MUSDFY2025 · Dec 31, 2025Research & Development
17.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
89.70KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.43USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.43USDFY2025 · Dec 31, 2025Basic Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-19.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.18MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-19.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.78KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.80MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
367.54KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
11.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.67MSharesUpdated Jul 19, 2026Float Shares
7.39MSharesUpdated Jul 19, 2026Shares Short
1.46MSharesUpdated Jul 19, 2026Short Ratio
8.68daysvs all stocks
Short % of Shares Outstanding
19.05%vs all stocks
% Held by Insiders
47.86%vs all stocks
% Held by Institutions
12.48%vs all stocks
Total Cash (MRQ)
10.51MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7160USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
2.01xvs Biotechnology peers
Book Value per Share (MRQ)
0.3590USDUpdated Jul 19, 2026Total Assets
6.18MUSDvs all stocks (USD)
Total Current Assets
6.18MUSDFY2025 · Dec 31, 2025Total Liabilities
5.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
5.82MUSDFY2025 · Dec 31, 2025Cash
6.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.18MUSDFY2025 · Dec 31, 2025Accounts Payable
4.87MUSDFY2025 · Dec 31, 2025Deferred Revenue
673.82KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.30KUSDFY2025 · Dec 31, 2025Retained Earnings
-87.14MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
353.22KUSDvs all stocks (USD)
52-Week Low
7.78USDUpdated Jul 19, 202652-Week High
34.10USDUpdated Jul 19, 202652-Week Change
38.78%vs all stocks
Beta
1.39xvs all stocks
50-Day MA
23.44USDUpdated Jul 19, 2026200-Day MA
20.02USDUpdated Jul 19, 2026Avg 10-Day Volume
134.44KSharesUpdated Jul 19, 2026Avg 30-Day Volume
141.45KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.61USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -676.7%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -6.77Industry median: -0.22Industry P5: -1.66Peers compared: 261
Return on assets is -211.3%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -2.11Industry median: -0.20Industry P5: -0.85Peers compared: 261
Price-to-book is 52.95×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 52.95Industry median: 2.97Industry P95: 23.50Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $239.55M, lower than 95% of all stocks globallySignificant
Market cap (USD): 239,548,354Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shenqi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Protara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk